Skip to main content
Premium Trial:

Request an Annual Quote

Luminex, Tecan Co-developing Newborn Screening Platform

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex and the Tecan Group today announced a collaboration to develop new automated screening platform for the faster detection of potential health risks in newborns.

The global original equipment manufacturing agreement will combine Luminex's xMAP technology and LX200 instrument with Tecan's Freedom EVO liquid handling platform and HydroFlex Washer.

Terms of the deal were not announced.

In a joint statement, Luminex said that it expects to launch the platform, to be called NeoPlex4, in 2011 and "once it receives regulatory clearance, [it] will be a fully automated, walk-away testing platform for multiplexed newborn screening." The platform, it added, will increase laboratory efficiency, save "vital resources," and allow researchers to analyze more samples more quickly.

NeoPlex4 will test newborn infants for several different biomarkers linked to critical diseases. The firms did not identify the diseases but said that they can cause "severe" mental and physical disability if untreated. "Multiplexing these test together from one sample offers significant improvements in testing efficiency," they said.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.